Interestingly though evidence in non-small cell lung cancer also point towards the idea that excessively decreasing vascular permeability and pruning after anti-VEGF therapy may negatively impact the outcome of combination therapy in patients and better treatments are achieved when anti-VEGF treatment results in improved tumor perfusion (92). Here, VEGFA is linked to non-small cell lung carcinoma.